Is Lucid Diagnostics going out of business?

Lucid Diagnostics Inc. (LUCD) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Lucid Diagnostics Inc. (LUCD) scores 29 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 92.59% (YoY)

Five questions, kept separate

Survival - Critical

Runway cannot be estimated from the available cash and cash-flow fields. Adjusted shares outstanding increased 92.6% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

26.2% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 92.59% (YoY)
• FCF margin: -991.97%
• Debt / Equity: 0.13x
• Interest coverage: -6335.5x
• Revenue CAGR (3Y): 131.97%
• Operating leverage: 2527.5%
• R&D intensity: 77.99%
• Return on Assets: -148.95%
• Cash Burn Deceleration: -63.52% QoQ improvement (Worsening)
• Working Capital Efficiency: 38.59x (Well-funded)
• Revenue Quality: Quality concerns (DSO +53d, Rev +27%)
• Revenue growth YoY: 26.74% (YoY) - Early-Stage Surge (low base)

Read from filings through 2026-08-12.

Price as of 2026-09-07.